Cereno Scientific AB (CRNO.B) Stock Overview

Cereno Scientific AB (publ), clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. Its lead drug candidate is CS1, a product candidate that is in Phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension and thrombotic indications. It is also involved in developing histone deacetylase inhibitor that is in the preclinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585, a new drug candidate for cardiovascular diseases; and Abbott with for use of CardioMEMS HF System in upcoming Phase II study with the company's CS1 drug candidate. Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Mölndal, Sweden.